华兰生物(002007) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥880,663,132.35, representing a 37.46% increase compared to ¥640,654,562.67 in the same period last year[3]. - Net profit attributable to shareholders was ¥351,676,291.89, a 50.37% increase from ¥233,867,429.26 year-on-year[3]. - The company reported a basic earnings per share of ¥0.1928, up 50.16% from ¥0.1284 in the same quarter last year[3]. - The company reported a net profit of ¥336,700,119.97 for Q1 2023, compared to ¥250,000,000.00 in Q1 2022, marking a growth of 34.6%[14]. - The net profit for Q1 2023 was CNY 382,366,154.95, representing an increase of 63.5% compared to CNY 233,548,562.12 in Q1 2022[15]. - The total profit for Q1 2023 was CNY 452,776,994.23, which is a 63.5% increase from CNY 276,877,118.83 in Q1 2022[15]. - The company achieved a total operating profit of CNY 452,445,402.74, which is an increase from CNY 277,212,415.83 in the same quarter last year[15]. Cash Flow and Investments - The net cash flow from operating activities increased by 531.54%, reaching ¥369,227,788.51 compared to ¥58,464,293.99 in the previous year[3]. - The cash flow from operating activities netted CNY 369,227,788.51, a significant increase from CNY 58,464,293.99 in the same period last year[16]. - The company’s investment activities resulted in a net cash outflow of CNY 737,127,823.13, an improvement from a net outflow of CNY 917,424,055.81 in the previous year[16]. - The cash flow from financing activities showed a net outflow of CNY 4,710,975.73, compared to a net inflow of CNY 2,245,892,044.42 in Q1 2022[17]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,081,329,145.54, a 2.31% increase from ¥14,740,966,166.50 at the end of the previous year[3]. - The company's total assets as of the end of Q1 2023 were ¥15,081,329,145.54, compared to ¥14,740,966,166.50 at the beginning of the year, reflecting a growth of 2.3%[13]. - Current assets decreased to ¥7,788,606,531.76 from ¥8,077,183,237.37, a decline of 3.6%[11]. - The total liabilities at the end of Q1 2023 were ¥2,481,179,344.39, down from ¥2,530,384,303.48, indicating a reduction of 1.9%[12]. - The company’s total equity attributable to shareholders increased by 3.43% to ¥10,755,099,480.27 from ¥10,398,562,106.26 at the end of the previous year[3]. - The equity attributable to shareholders of the parent company increased to ¥10,755,099,480.27 from ¥10,398,562,106.26, a rise of 3.4%[13]. Expenses - Total operating costs for Q1 2023 were ¥543,963,012.38, up 39.4% from ¥390,032,981.03 in Q1 2022[14]. - Research and development expenses amounted to ¥77,578,545.59, representing a 21.7% increase from ¥63,757,662.28 in the previous year[14]. - The company experienced a 384.19% increase in sales expenses, attributed to higher service fees related to increased sales revenue[6]. Other Income and Gains - Investment income rose by 194.76%, primarily due to increased returns from financial products[6]. - The company reported a significant increase of 551.82% in fair value gains, driven by changes in the fair value of financial products[6]. - The company’s other comprehensive income attributable to shareholders was CNY 351,676,291.89, compared to CNY 233,867,429.26 in Q1 2022, marking a growth of 50.4%[15]. Future Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[14].